Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma

類似資料

• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  著者:: Crusoe, Edvan De Queiroz, 等
  出版事項: (2020)
• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
  著者:: Voorhees, Peter M., 等
  出版事項: (2020)
• Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
  著者:: Ajay K. Nooka, 等
  出版事項: (2022-04-01)
• Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
  著者:: Yimer, Habte, 等
  出版事項: (2019)
• Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
  著者:: Ashrafi, Farzaneh, 等
  出版事項: (2020)